---
title: Quantitative Clinical Pharmacology & PopPK Modeling | CBS
description: "Quantitative clinical pharmacology for biologics and ADCs: NCA, population PK/PD, exposure-response, QSP, FIH dose selection and CDISC deliverables."
image: https://www.crystalbiosolutions.com/hubfs/website-assets/clinical%20pharmacology.jpg
---

![Crystal Bio Solutions logo](https://www.crystalbiosolutions.com/hs-fs/hubfs/Crystal%20Bio%20Solutions%20logo.webp?width=330&height=150&name=Crystal%20Bio%20Solutions%20logo.webp)

- Bioanalysis & Biomarkers 
    - [All Bioanalysis & Biomarker Services](https://www.crystalbiosolutions.com/services/bioanalysis-and-biomarkers)
    - [PK Assays for Biologics & ADCs](https://www.crystalbiosolutions.com/services/pk-bioanalysis)
    - [NAb & ADA Immunogenicity Assays](https://www.crystalbiosolutions.com/ada-and-nab-testing-in-biologics-pk-efficacy-and-regulatory-risk)
    - [Receptor Occupancy Assays](https://www.crystalbiosolutions.com/services/receptor-occupancy-assays)
- Biologics CMC Analytical 
    - [All Biologics CMC Analytical Services](https://www.crystalbiosolutions.com/characterization-cmc-analytical)
    - [Developability Assessment](https://www.crystalbiosolutions.com/services/biologics-developability-assessment)
    - [Extended Characterization by HRMS](https://www.crystalbiosolutions.com/services/biologics-extended-characterization-hrms)
    - [Biotransformation & In Vivo CQA](https://www.crystalbiosolutions.com/services/biotransformation-in-vivo-cqa)
- [Clinical Pharmacology](https://www.crystalbiosolutions.com/services/clinical-pharmacology)
- Solutions 
    - [ADC Programs](https://www.crystalbiosolutions.com/antibody-drug-conjugates-adc)
    - [Regulatory Affairs Support](https://www.crystalbiosolutions.com/services/regulatory-affairs-biologics-adc-cgt)
    - [Clinical Support](https://www.crystalbiosolutions.com/clinical-research-services)

- [Resources](https://www.crystalbiosolutions.com/news-and-events)
- [Case Studies](https://www.crystalbiosolutions.com/news-and-events/tag/case-study)
- [About Us](https://www.crystalbiosolutions.com/about-us)
- [Locations](https://www.crystalbiosolutions.com/locations)
- [Careers](https://www.crystalbiosolutions.com/careers-at-crystal-bio-solutions)
- [Request a Proposal](https://www.crystalbiosolutions.com/contact-us)

![Clinical pharmacology modeling and data analysis](https://www.crystalbiosolutions.com/hs-fs/hubfs/website-assets/clinical%20pharmacology.jpg?width=960&height=640&name=clinical%20pharmacology.jpg)

# Quantitative Clinical Pharmacology

Crystal Bio Solutions provides quantitative clinical pharmacology (pharmacometrics) for biologics, ADCs and other modalities: noncompartmental analysis, population PK/PD, exposure-response, translational modeling and QSP, with SAS programming and CDISC deliverables for regulatory submissions. Our team supports programs from nonclinical translation and first-in-human dose selection through late-stage development.

[![Let's talk](https://hubspot-no-cache-eu1-prod.s3.amazonaws.com/cta/default/146565877/interactive-264126601418.png)](https://www.crystalbiosolutions.com/hs/cta/wi/redirect?encryptedPayload=AVxigLKjmFIKxgyScG2oTfQD49qlU2CbltZtM1KkXojKxYGWLkCIXYFhmklQ7rMNNK4UK0Y%2BGw7P5UlL3nfdA4%2FR8CBaoIL7Ek%2FHzihds6OpPLUnvsmjt8%2BVHQLi9nVR4f1cL%2FKJx5Bi6gHTTn4gt9T3hECcMP2vGKymu1GWspkG9dspsJ7awuxW1ZgoCIsEzsgmmaPNkIqt5vXFqnUCt%2F06RQXh6qTa&webInteractiveContentId=264126601418&portalId=146565877&hsLang=en)

![CBS orange-blue banner-1](https://www.crystalbiosolutions.com/hs-fs/hubfs/CBS%20orange-blue%20banner-1.png?width=2000&height=21&name=CBS%20orange-blue%20banner-1.png "CBS orange-blue banner-1")

Noncompartmental PK/TK Analysis and Reporting Noncompartmental analysis of PK and TK data using software with 21 CFR Part 11 controls. Standard outputs include concentration-time plots, exposure metrics, accumulation and linearity assessments, and tables, figures and narratives for toxicology reports and clinical study reports. Statistical Programming

SAS programming with CDISC compliance: SEND for nonclinical, SDTM and ADaM for clinical, TLF packages, define.xml, reviewer guides, and validation with Pinnacle 21 to support IND, CTA, and BLA/MAA submissions. Translational Modeling and Simulations Quantitative integration of nonclinical pharmacology, DMPK, and toxicology to project clinical PK/PD, set the first-in-human dose, evaluate DDI and QT risk, and test scenarios that inform study design and enrollment strategy. Pharmacometrics Population PK/PD modeling and exposure-response analyses for dose selection, enrichment, endpoint justification, covariate and subpopulation assessment, and trial simulations that de-risk pivotal plans and regulatory reviews. Quantitative Systems Pharmacology (QSP) Mechanistic, multi-scale models that link target engagement to pathway, disease biology, and clinical endpoints. QSP supports indication selection, biomarker strategy, and optimization of therapeutic interventions. Expert Consultation

Hands-on guidance from senior scientists for study design, SAP alignment, decision frameworks, and authority interactions. Outputs are quality-reviewed and aligned with ICH expectations.

![CBS orange banner-1](https://www.crystalbiosolutions.com/hs-fs/hubfs/website-assets/CBS%20orange%20banner-1.png?width=2000&height=24&name=CBS%20orange%20banner-1.png "CBS orange banner-1")

![Pharmacometric model diagrams and PK plots used for model-informed drug development.](https://www.crystalbiosolutions.com/hs-fs/hubfs/Pharmacokinetic%20and%20Tumor%20Response%20Modeling%20in%20Clinical%20Research.webp?width=640&height=480&name=Pharmacokinetic%20and%20Tumor%20Response%20Modeling%20in%20Clinical%20Research.webp) Model-Informed Drug Development (MIDD) We build quantitative pharmacostatistical models that describe PK, efficacy, and safety, then run simulations to compare clinical scenarios. Outputs inform first-in-human dose, adaptive or enrichment strategies, endpoint selection, and patient or indication prioritization. We also prepare briefing packages and responses for authority meetings and support NDA, BLA, and MAA filings. ![Clinical pharmacology team collaborating on global drug development strategy.](https://www.crystalbiosolutions.com/hs-fs/hubfs/Collaborative%20Problem-Solving%20at%20the%20Workplace.webp?width=640&height=480&name=Collaborative%20Problem-Solving%20at%20the%20Workplace.webp) Global Drug Development and Launch Teams in the US, China, and EU coordinate with our regulatory, clinical, and bioanalytical groups to deliver coherent global plans. Services cover regional strategy and bridging, labeling and claims planning, and launch-readiness activities, so sponsors move from pivotal data to approval with confidence.

## Frequently Asked Questions

 

### What is model-informed drug development (MIDD)?

MIDD uses quantitative models of pharmacokinetics, pharmacodynamics, disease and exposure-response to inform development and regulatory decisions, such as dose selection, trial design and labeling. ICH M15, General Principles for Model-Informed Drug Development (adopted January 2026 and issued by FDA as final guidance in June 2026), sets out harmonized principles for planning, evaluating and documenting MIDD evidence.

 

### How is the first-in-human dose selected?

First-in-human dose selection integrates nonclinical pharmacology, toxicology and PK. Common approaches include the human equivalent dose derived from the NOAEL with safety factors, and, for higher-risk biologics, the minimal anticipated biological effect level (MABEL). Translational PK/PD modeling helps reconcile these approaches and plan dose escalation.

 

### When is population PK analysis used?

Population PK uses sparse or rich data across many subjects to describe typical PK and its variability, and to identify covariates such as body weight, organ function or anti-drug antibodies that affect exposure. It supports dose justification, special-population dosing and labeling.

 

### What is dose optimization under FDA Project Optimus?

Project Optimus is an FDA Oncology Center of Excellence initiative encouraging sponsors to identify an optimized dose rather than defaulting to the maximum tolerated dose. Programs are expected to compare multiple doses, often in randomized evaluations, and to use exposure-response and safety data to support the selected dose.

 

### Which CDISC deliverables do you provide?

SEND datasets for nonclinical studies, SDTM and ADaM datasets for clinical studies, tables, listings and figures, define.xml files and reviewer guides, validated with Pinnacle 21 to support IND, CTA, BLA and MAA submissions.

 

### What is quantitative systems pharmacology (QSP) and when is it useful?

QSP builds mechanistic models that link target engagement to pathway biology, disease progression and clinical endpoints. It is useful for indication selection, biomarker strategy, combination therapy questions and early decisions when clinical data are limited.

 

## Related reading

- [Clinical Dose Optimization: From Phase 2 Dose Finding to FDA Project Optimus](https://www.crystalbiosolutions.com/news-and-events/clinical-dose-optimization-from-phase-2-dose-finding-to-fda-project-optimus?hsLang=en)
- [Population PK/PD Modeling That Starts With Better Bioanalysis](https://www.crystalbiosolutions.com/news-and-events/population-pk/pd-modeling-that-starts-with-better-bioanalysis?hsLang=en)

[See all scientific articles](https://www.crystalbiosolutions.com/news-and-events/tag/blog?hsLang=en)

Discuss your program with Dr. Lorin Roskos, our Chief Scientific Officer

Bring a real PK/PD modeling or dose-selection question to the leader who supervises our quantitative clinical pharmacology projects. One hour at no cost, with a CDA in place first. Our business development team replies within one business day.

[Request a Consultation](https://www.crystalbiosolutions.com/scientific-consultation?hsLang=en)

## Ready to Start a Project?

Tell us about your study. Our business development team replies within one business day.

[Request a Proposal](https://www.crystalbiosolutions.com/contact-us?hsLang=en)

![Crystal Bio Solutions logo (footer)](https://www.crystalbiosolutions.com/hubfs/Logo_CBS-%E7%AB%96%E7%89%88-%E5%8F%8D%E7%99%BD.png)

- [Our Services](https://www.crystalbiosolutions.com) 
    - [Bioanalysis & Biomarkers](https://www.crystalbiosolutions.com/services/bioanalysis-and-biomarkers)
    - [Biologics CMC Analytical](https://www.crystalbiosolutions.com/characterization-cmc-analytical)
    - [Clinical Pharmacology](https://www.crystalbiosolutions.com/services/clinical-pharmacology)
    - [Regulatory Affairs](https://www.crystalbiosolutions.com/services/regulatory-affairs-biologics-adc-cgt)
    - [Clinical Support](https://www.crystalbiosolutions.com/clinical-research-services)
- [Information](https://www.crystalbiosolutions.com/news-and-events) 
    - [About Us](https://www.crystalbiosolutions.com/about-us)
    - [Quality & Compliance](https://www.crystalbiosolutions.com/quality-and-compliance)
    - [News & Events](https://www.crystalbiosolutions.com/news-and-events)
    - [Case Studies](https://www.crystalbiosolutions.com/news-and-events/tag/case-study)
    - [Scientific Articles](https://www.crystalbiosolutions.com/news-and-events/tag/blog)
    - [Careers](https://www.crystalbiosolutions.com/careers-at-crystal-bio-solutions)
- [Contact](https://www.crystalbiosolutions.com/contact-us) 
    - [Email Us](mailto:cbs_bd@crystalpharmatech.com)
    - [Contact Form](https://www.crystalbiosolutions.com/contact-us)
    - [Our Locations](https://www.crystalbiosolutions.com/locations)
    - [Crystal Group](https://www.crystalbiosolutions.com/about-us#crystal-group) 
          - [Crystal Pharmatech](https://www.crystalpharmatech.com/)
          - [Crystal NAX](https://www.crystalnax.com/)

<https://www.linkedin.com/company/crystal-bio-solutions/> [Follow us on LinkedIn News, events and openings](https://www.linkedin.com/company/crystal-bio-solutions/)

- [Privacy Policy](https://www.crystalbiosolutions.com/policies/privacy-policy)
- [Terms of Service](https://www.crystalbiosolutions.com/policies/terms-of-service)

Copyright © 2026 Crystal Bio Solutions, Inc. All rights reserved.

```json
{
  "@context" : "https://schema.org",
  "@id" : "https://www.crystalbiosolutions.com/#organization",
  "@type" : "Organization",
  "alternateName" : "CBS",
  "contactPoint" : [ {
    "@type" : "ContactPoint",
    "contactType" : "sales",
    "email" : "cbs_bd@crystalpharmatech.com",
    "url" : "https://www.crystalbiosolutions.com/contact-us"
  } ],
  "logo" : "https://www.crystalbiosolutions.com/hs-fs/hubfs/CBS%20VI%20v2/CBS%20Logo.png",
  "name" : "Crystal Bio Solutions",
  "parentOrganization" : {
    "@type" : "Organization",
    "name" : "Crystal Group",
    "url" : "https://www.crystalpharmatech.com/"
  },
  "sameAs" : [ "https://www.linkedin.com/company/crystal-bio-solutions/" ],
  "url" : "https://www.crystalbiosolutions.com/"
}
```

```json
{
  "@context" : "https://schema.org",
  "@id" : "https://www.crystalbiosolutions.com/#website",
  "@type" : "WebSite",
  "inLanguage" : "en",
  "name" : "Crystal Bio Solutions",
  "publisher" : {
    "@id" : "https://www.crystalbiosolutions.com/#organization"
  },
  "url" : "https://www.crystalbiosolutions.com/"
}
```

```json
{
  "@context" : "https://schema.org",
  "@id" : "https://www.crystalbiosolutions.com/services/clinical-pharmacology/#webpage",
  "@type" : "WebPage",
  "about" : {
    "@id" : "https://www.crystalbiosolutions.com/services/clinical-pharmacology/#service"
  },
  "breadcrumb" : {
    "@id" : "https://www.crystalbiosolutions.com/services/clinical-pharmacology/#breadcrumb"
  },
  "description" : "Quantitative clinical pharmacology for biologics and ADCs: NCA, population PK/PD, exposure-response, QSP, FIH dose selection and CDISC deliverables.",
  "inLanguage" : "en",
  "isPartOf" : {
    "@id" : "https://www.crystalbiosolutions.com/#website"
  },
  "name" : "Quantitative Clinical Pharmacology: PK/PD and PopPK Modeling | CBS",
  "url" : "https://www.crystalbiosolutions.com/services/clinical-pharmacology"
}
```

```json
{
  "@context" : "https://schema.org",
  "@id" : "https://www.crystalbiosolutions.com/services/clinical-pharmacology/#service",
  "@type" : "Service",
  "alternateName" : [ "Clinical Pharmacology", "Pharmacometrics" ],
  "areaServed" : "Worldwide",
  "description" : "Biometrics, pharmacometrics, and modeling and simulation across the development lifecycle, including SAS/CDISC deliverables, NCA, population PK/PD, QSP, and documentation to support regulatory submissions.",
  "hasOfferCatalog" : {
    "@type" : "OfferCatalog",
    "itemListElement" : [ {
      "@type" : "Offer",
      "itemOffered" : {
        "@type" : "Service",
        "name" : "Noncompartmental PK/TK analysis and reporting"
      }
    }, {
      "@type" : "Offer",
      "itemOffered" : {
        "@type" : "Service",
        "name" : "Statistical programming (SAS, CDISC)"
      }
    }, {
      "@type" : "Offer",
      "itemOffered" : {
        "@type" : "Service",
        "name" : "Translational modeling and simulation"
      }
    }, {
      "@type" : "Offer",
      "itemOffered" : {
        "@type" : "Service",
        "name" : "Pharmacometrics (population PK/PD, exposure-response)"
      }
    }, {
      "@type" : "Offer",
      "itemOffered" : {
        "@type" : "Service",
        "name" : "Quantitative systems pharmacology (QSP)"
      }
    }, {
      "@type" : "Offer",
      "itemOffered" : {
        "@type" : "Service",
        "name" : "Expert consultation"
      }
    } ],
    "name" : "Quantitative Clinical Pharmacology"
  },
  "name" : "Quantitative Clinical Pharmacology",
  "provider" : {
    "@id" : "https://www.crystalbiosolutions.com/#organization"
  },
  "url" : "https://www.crystalbiosolutions.com/services/clinical-pharmacology"
}
```

```json
{
  "@context" : "https://schema.org",
  "@id" : "https://www.crystalbiosolutions.com/services/clinical-pharmacology/#breadcrumb",
  "@type" : "BreadcrumbList",
  "itemListElement" : [ {
    "@type" : "ListItem",
    "item" : "https://www.crystalbiosolutions.com/",
    "name" : "Home",
    "position" : 1
  }, {
    "@type" : "ListItem",
    "item" : "https://www.crystalbiosolutions.com/services/clinical-pharmacology",
    "name" : "Quantitative Clinical Pharmacology",
    "position" : 2
  } ]
}
```

```json
{
  "@context" : "https://schema.org",
  "@id" : "https://www.crystalbiosolutions.com/services/clinical-pharmacology/#faq",
  "@type" : "FAQPage",
  "mainEntity" : [ {
    "@type" : "Question",
    "acceptedAnswer" : {
      "@type" : "Answer",
      "text" : "MIDD uses quantitative models of pharmacokinetics, pharmacodynamics, disease and exposure-response to inform development and regulatory decisions, such as dose selection, trial design and labeling. ICH M15, General Principles for Model-Informed Drug Development (adopted January 2026 and issued by FDA as final guidance in June 2026), sets out harmonized principles for planning, evaluating and documenting MIDD evidence."
    },
    "name" : "What is model-informed drug development (MIDD)?"
  }, {
    "@type" : "Question",
    "acceptedAnswer" : {
      "@type" : "Answer",
      "text" : "First-in-human dose selection integrates nonclinical pharmacology, toxicology and PK. Common approaches include the human equivalent dose derived from the NOAEL with safety factors, and, for higher-risk biologics, the minimal anticipated biological effect level (MABEL). Translational PK/PD modeling helps reconcile these approaches and plan dose escalation."
    },
    "name" : "How is the first-in-human dose selected?"
  }, {
    "@type" : "Question",
    "acceptedAnswer" : {
      "@type" : "Answer",
      "text" : "Population PK uses sparse or rich data across many subjects to describe typical PK and its variability, and to identify covariates such as body weight, organ function or anti-drug antibodies that affect exposure. It supports dose justification, special-population dosing and labeling."
    },
    "name" : "When is population PK analysis used?"
  }, {
    "@type" : "Question",
    "acceptedAnswer" : {
      "@type" : "Answer",
      "text" : "Project Optimus is an FDA Oncology Center of Excellence initiative encouraging sponsors to identify an optimized dose rather than defaulting to the maximum tolerated dose. Programs are expected to compare multiple doses, often in randomized evaluations, and to use exposure-response and safety data to support the selected dose."
    },
    "name" : "What is dose optimization under FDA Project Optimus?"
  }, {
    "@type" : "Question",
    "acceptedAnswer" : {
      "@type" : "Answer",
      "text" : "SEND datasets for nonclinical studies, SDTM and ADaM datasets for clinical studies, tables, listings and figures, define.xml files and reviewer guides, validated with Pinnacle 21 to support IND, CTA, BLA and MAA submissions."
    },
    "name" : "Which CDISC deliverables do you provide?"
  }, {
    "@type" : "Question",
    "acceptedAnswer" : {
      "@type" : "Answer",
      "text" : "QSP builds mechanistic models that link target engagement to pathway biology, disease progression and clinical endpoints. It is useful for indication selection, biomarker strategy, combination therapy questions and early decisions when clinical data are limited."
    },
    "name" : "What is quantitative systems pharmacology (QSP) and when is it useful?"
  } ],
  "url" : "https://www.crystalbiosolutions.com/services/clinical-pharmacology"
}
```